Oxford BioDynamics (LON:OBD), a biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture, for use within the pharmaceutical and biotechnology industry, noted that Mitsubishi Tanabe Pharma America, Inc. has announced that the first patient has been enrolled in the REFINE-ALS clinical study, designed to identify and measure specific biomarkers and clinical assessments in up to 300 people with amyotrophic lateral sclerosis (ALS) in the United States who have begun treatment on RADICAVA® (edaravone).
As part of the trial, Mitsubishi Tanabe Pharma America, its partners, and trial investigators, will use OBD’s proprietary EpiSwitch™ technology platform to assess the rate of ALS disease progression using highly novel epigenetic biomarkers.
The full text of the announcement from Mitsubishi Tanabe Pharma America, Inc. is as follows:
FIRST PATIENT ENROLLED IN MTPA REFINE-ALS BIOMARKER STUDY
Study is Company’s First Clinical Research in the United States
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the first patient has been enrolled in the REFINE-ALS clinical study, designed to identify and measure specific biomarkers and clinical assessments in up to 300 people with amyotrophic lateral sclerosis (ALS) in the United States who have begun treatment on RADICAVA® (edaravone).
“We are honored to be working with so many esteemed collaborators on this novel study and excited to have reached this milestone of enrolling the first patient,” said Stephen Apple, M.D., Senior Medical Director, Medical Affairs, MTPA. “This research has great potential to provide a deeper understanding of the biological effects of RADICAVA.”
REFINE-ALS, sponsored by MTPA and led by Massachusetts General Hospital (MGH) Neurological Clinical Research Institute (NCRI), includes approximately 40 sites across the country and will utilize the expertise of multiple specialty laboratories to assess biomarker samples.
The study includes assessments of biomarkers for oxidative stress, inflammation, neuronal and muscle injury. Biomarkers will be measured prior to initiating treatment with RADICAVA, at the start of treatment, and at pre-specified time points throughout the 24-week study period (six cycles of treatment). Interim results are expected in 2020.
“ALS is a multifaceted and complex disease with few treatment options,” said primary investigator James Berry, M.D., M.P.H., MGH NCRI, Boston. “We’re proud to be investigating the biological impact of RADICAVA on this disease using a combination of genomic analysis and cutting edge biomarker platforms, potentially enhancing our understanding of the disease and its treatments and improving clinical treatment plans for people with ALS.”
As part of the study, investigators will utilize cutting-edge technology such as Oxford BioDynamics’ proprietary EpiSwitch™, which assesses a novel class of epigenetic biomarkers aimed at understanding the rate of disease progression. Additionally, SomaLogic’s SomaScan® technology will measure the changing levels of approximately 5,000 proteins throughout the body, providing a comprehensive and real-time picture of biologic activity and insights that have the potential to further understanding of a treatment’s effect.
About Mitsubishi Tanabe Pharma America, Inc.
Based in Jersey City, N.J., Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation’s (MTPC) 100 percent owned U.S. holding company, Mitsubishi Tanabe Pharma Holdings America, Inc. MTPA is dedicated to delivering innovative products that address the unmet medical needs of patients in North America. It was established by MTPC to commercialize approved pharmaceutical products in North America with plans to expand its product line through collaborations with partners. For more information, please visit www.mt-pharma-america.com or follow us on Twitter and Facebook.
Overview of Mitsubishi Tanabe Pharma Corporation (MTPC)
Mitsubishi Tanabe Pharma, which was founded in 1678, has its headquarters in Doshomachi, Osaka, which is the birthplace of Japan’s pharmaceutical industry. With business centered on ethical pharmaceuticals, Mitsubishi Tanabe Pharma is a well-established company and has the longest history of any listed company in Japan.1 In accordance with the corporate philosophy of “contributing to the healthier lives of people around the world through the creation of pharmaceuticals,” the Company formulated the key concept of Open Up the Future under the Medium-Term Management Plan 2016-2020. Through the discovery of drugs that address unmet medical needs, centered on its priority disease areas – autoimmune diseases, diabetes and kidney diseases, central nervous system diseases, and vaccines – Mitsubishi Tanabe Pharma will strive to contribute to the health of patients around the world. MTPC is the parent company of MTPA and the license holder of RADICAVA. For more information, go to http://www.mt-pharma.co.jp/.
About RADICAVA® (edaravone)
The U.S. Food and Drug Administration approved RADICAVA® (edaravone) on May 5, 2017 as a treatment for amyotrophic lateral sclerosis.2 In a pivotal trial, people given RADICAVA experienced a 33 percent slower rate of decline in the loss of physical function, compared to placebo as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R), a validated rating instrument for monitoring the progression of disability in people with ALS.3,4
Edaravone was discovered and developed for ALS by Mitsubishi Tanabe Pharma Corporation (MTPC) and commercialized in the U.S. by Mitsubishi Tanabe Pharma America, Inc. MTPC group companies began researching ALS in 2001 through an iterative clinical platform over a 13-year period. In 2015, edaravone was approved for use as a treatment for ALS in Japan and South Korea.
Marketing authorization was granted in Canada in October 2018 and Switzerland in January 2019.
IMPORTANT SAFETY INFORMATION
Before you receive RADICAVA, tell your healthcare provider about all of your medical conditions, including if you:
· have asthma.
· are allergic to other medicines.
· are pregnant or plan to become pregnant. It is not known if RADICAVA will harm your unborn baby.
· are breastfeeding or plan to breastfeed. It is not known if RADICAVA passes into your breast milk. You and your healthcare provider should decide if you will receive RADICAVA or breastfeed.
Tell your healthcare provider about all the medicines you take, including prescription and over-the counter medicines, vitamins, and herbal supplements.
What are the possible side effects of RADICAVA?
· RADICAVA may cause serious side effects including hypersensitivity (allergic) reactions and sulfite allergic reactions.
· Hypersensitivity reactions have happened in people receiving RADICAVA and can happen after your infusion is finished.
· RADICAVA contains sodium bisulfite, a sulfite that may cause a type of allergic reaction that can be serious and life-threatening. Sodium bisulfite can also cause less severe asthma episodes in certain people. Sulfite sensitivity can happen more often in people who have asthma than in people who do not have asthma.
· Tell your healthcare provider right away or go to the nearest emergency room if you have any of the following symptoms: hives; swelling of the lips, tongue, or face; fainting; breathing problems; wheezing; trouble swallowing; dizziness; itching; or an asthma attack (in people with asthma).
· Your healthcare provider will monitor you during treatment to watch for signs and symptoms of all the serious side effects.
The most common side effects of RADICAVA include bruising (contusion), problems walking (gait disturbance), and headache.
These are not all the possible side effects of RADICAVA. Call your healthcare provider for medical advice about side effects. You may report side effects to Mitsubishi Tanabe Pharma America, Inc. at 1-888-292-0058 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.